Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

PIRS

Pieris Pharmaceuticals Inc

Apr 26 • 04:00PM ET

11.72

Dollar change +0.12
Percentage change 1.03	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-22.94	Insider Own	0.00%	Shs Outstand	1.24M	Perf Week	1.03%
Market Cap	14.53M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	1.24M	Perf Month	-24.37%
Income	-24.54M	PEG	-	EPS next Q	-	Inst Own	39.08%	Short Float	0.02%	Perf Quarter	-10.67%
Sales	42.81M	P/S	0.34	EPS this Y	-	Inst Trans	-4.23%	Short Ratio	0.03	Perf Half Y	-40.16%
Book/sh	21.64	P/B	0.54	EPS next Y	-	ROA	-36.58%	Short Interest	0.00M	Perf Year	-81.10%
Cash/sh	21.27	P/C	0.55	EPS next 5Y	-	ROE	-89.76%	52W Range	10.89 - 80.80	Perf YTD	-19.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.57%	ROI	-91.72%	52W High	-85.50%	Beta	0.55
Dividend TTM	-	Quick Ratio	3.24	Sales past 5Y	15.45%	Gross Margin	94.47%	52W Low	7.64%	ATR (14)	1.13
Dividend Ex-Date	-	Current Ratio	3.24	EPS Y/Y TTM	36.07%	Oper. Margin	-37.01%	RSI (14)	34.68	Volatility	7.34% 7.46%
Employees	50	Debt/Eq	0.00	Sales Y/Y TTM	65.28%	Profit Margin	-57.33%	Recom	1.67	Target Price	560.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	57.42%	Payout	-	Rel Volume	1.53	Prev Close	11.60
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-77.78%	Earnings	-	Avg Volume	11.08K	Price	11.72
SMA20	-11.95%	SMA50	-15.01%	SMA200	-33.47%	Trades		Volume	16,959	Change	1.03%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform	$5
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform	$5
Mar-19-18	Initiated	Jefferies	Buy	$12
Mar-19-18	Initiated	Evercore ISI	Outperform	$13
Jan-16-18	Reiterated	H.C. Wainwright	Buy	$9 → $12
May-30-17	Initiated	Rodman & Renshaw	Buy	$9
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform	$8
Jul-22-15	Initiated	ROTH Capital	Buy	$7

Show Previous Ratings

Apr-19-24 12:10PM	Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split (ACCESSWIRE) -6.60%
Mar-27-24 08:00AM	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential (ACCESSWIRE)
Nov-14-23 05:36PM	Pieris Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
Sep-25-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why (Zacks)
Aug-24-23 12:32PM	Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis (GuruFocus.com)
12:00PM	Loading…
Aug-23-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +19.68%
Aug-17-23 08:00AM	Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific (ACCESSWIRE) +8.06%
Jul-19-23 02:02PM	Pieris lays off most staff after AstraZeneca pulls out of partnership (American City Business Journals)
08:40AM	Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises (Zacks)
Jul-18-23 01:59PM	Why Pieris Pharmaceuticals Shares Shooting Higher Today? (Benzinga) +11.81%
09:15AM	Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring (ACCESSWIRE)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks) +12.02%
Jun-21-23 07:00AM	Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study (ACCESSWIRE) -70.86%
Jun-11-23 10:28AM	We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate (Simply Wall St.)
04:30PM	Loading…
Jun-02-23 04:30PM	Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference (ACCESSWIRE) +5.35%
May-22-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference (ACCESSWIRE) +6.00%
May-21-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference (ACCESSWIRE)
May-15-23 06:07AM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 01:41PM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript (Insider Monkey) +10.60%
May-10-23 08:15AM	Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates (ACCESSWIRE)
May-05-23 06:41AM	Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +7.42%
May-04-23 08:00AM	Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) (ACCESSWIRE)
May-02-23 04:30PM	Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023 (ACCESSWIRE)
Apr-17-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting (ACCESSWIRE) +14.89%
Apr-01-23 12:47PM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:10AM	Pieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021) (Simply Wall St.) -5.24%
Mar-29-23 05:00PM	Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively (Benzinga) -28.38%
08:35AM	Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates (ACCESSWIRE)
Mar-24-23 05:00PM	Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023 (ACCESSWIRE)
Feb-19-23 07:39AM	Pieris Pharmaceuticals (NASDAQ:PIRS) shareholders have endured a 81% loss from investing in the stock five years ago (Simply Wall St.)
Feb-14-23 05:40AM	Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains? (Zacks)
Jan-17-23 07:10AM	While institutions own 32% of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), individual investors are its largest shareholders with 40% ownership (Simply Wall St.) -16.67%
Jan-10-23 08:00AM	Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346) (ACCESSWIRE) +10.16%
Dec-21-22 06:01AM	Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Could Be Quite Risky (Simply Wall St.)
Nov-23-22 08:00AM	Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference (ACCESSWIRE) +6.26%
Nov-09-22 08:00AM	Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference (ACCESSWIRE) -7.30%
Nov-02-22 08:35AM	Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-01-22 09:15AM	Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220 (ACCESSWIRE)
Oct-26-22 08:00AM	Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022 (ACCESSWIRE)
Sep-12-22 08:03AM	Shareholders in Pieris Pharmaceuticals (NASDAQ:PIRS) are in the red if they invested a year ago (Simply Wall St.)
Sep-08-22 04:01PM	Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Aug-24-22 10:34AM	Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate (Benzinga) +5.33%
08:00AM	Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS (ACCESSWIRE)
Aug-10-22 06:20AM	One Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analyst Is Reducing Their Forecasts For This Year (Simply Wall St.)
Aug-04-22 02:03PM	Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs (Benzinga) -5.49%
09:35AM	Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-28-22 07:20AM	Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022 (ACCESSWIRE)
Jul-14-22 06:29AM	Here's Why We're Not Too Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Situation (Simply Wall St.)
Jun-02-22 08:00AM	Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference (ACCESSWIRE)
May-18-22 09:35AM	Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:00AM	Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference (ACCESSWIRE)
May-16-22 09:35AM	After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS) (Zacks)
08:29AM	How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own? (Simply Wall St.)
May-11-22 08:45AM	Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -20.44%
07:00AM	Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-04-22 08:00AM	Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022 (ACCESSWIRE)
Apr-15-22 11:00AM	3 Risky Stocks With Huge Potential Upside (Motley Fool)
Apr-09-22 06:00AM	This Pharmaceutical Stock Could Be Your Lottery Ticket (Motley Fool)
Apr-08-22 06:15AM	This Pharmaceutical Stock Could Bank Billions Soon (Motley Fool)
Apr-05-22 12:00PM	Pieris Pharmaceuticals' (NASDAQ:PIRS) investors will be pleased with their favorable 34% return over the last five years (Simply Wall St.)
Mar-04-22 04:00PM	Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off. (Motley Fool) -5.47%
Mar-01-22 11:05AM	Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-28-22 09:25AM	Heska (HSKA) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-23-22 08:00AM	Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022 (ACCESSWIRE)
Feb-04-22 08:58AM	Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-28-22 08:00AM	HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors (GlobeNewswire)
Jan-27-22 06:23PM	3 Biotechs That Will Soar Regardless of COVID-19 (Motley Fool) -6.32%
Jan-16-22 10:30AM	2 Risky Growth Stocks That Could Make You Filthy Rich (Motley Fool)
Jan-14-22 08:00AM	Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 41BB/HER2 Bispecific Cinrebafusp Alfa (ACCESSWIRE)
Jan-03-22 07:00AM	Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402 (ACCESSWIRE)
Dec-15-21 12:53PM	Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't? (Zacks)
Dec-06-21 09:33AM	How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own? (Simply Wall St.)
Nov-11-21 08:05AM	Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences (ACCESSWIRE)
Nov-08-21 08:00AM	Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012 (ACCESSWIRE)
Nov-02-21 09:05AM	Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Oct-26-21 08:00AM	Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021 (ACCESSWIRE)
Oct-14-21 10:00AM	2 Penny Stocks That Could Soar Soon (Motley Fool)
Oct-06-21 08:00AM	Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer (ACCESSWIRE)
Sep-09-21 08:00AM	Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences (ACCESSWIRE) +8.99%
Sep-08-21 10:31AM	2 Stocks I Bought Last Week (Motley Fool)
Aug-27-21 10:40AM	Which Biotech Stock Will Shock the Market in 2022? (Motley Fool)
Aug-24-21 09:00AM	Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor (ACCESSWIRE)
Aug-06-21 09:42AM	Party Time: Brokers Just Made Major Increases To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Earnings Forecasts (Simply Wall St.)
Aug-04-21 09:25AM	Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-03-21 08:00AM	Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team (ACCESSWIRE)
Jul-28-21 08:00AM	Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021 (ACCESSWIRE)
Jun-30-21 08:31AM	This Risky Micro-Cap Could Pay Off Big (Motley Fool)
Jun-25-21 09:24AM	Akumin To Acquire Alliance HealthCare Services With An Enterprise Value Of $820M (Benzinga) -8.47%
07:00AM	Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis (ACCESSWIRE)
06:18AM	What Makes Penny Stock Pieris Pharma A Strong Buy? (TipRanks)
05:23AM	Pieris Jumps on Grant for Drug to Treat Lung Scarring From COVID (TheStreet.com)
Jun-24-21 10:03AM	3 Top Stocks Under $10 (Motley Fool) +23.45%

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIRITSY CHRISTOPHER P	Director	May 25 '23	Buy	0.85	10,000	8,500	20,000	May 30 04:21 PM

Open in Screener

WTW

Willis Towers Watson Public Limited Co

Apr 26 • 04:00PM ET

250.95

Dollar change -5.97
Percentage change -2.32	%

Financial • Insurance Brokers • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

WTW Willis Towers Watson Public Limited Co daily Stock Chart

Held by: VTI VOO VO IVV VTV VOE RSP USMV IWR IWD

Index	S&P 500	P/E	25.14	EPS (ttm)	9.98	Insider Own	0.40%	Shs Outstand	102.54M	Perf Week	-5.13%
Market Cap	25.72B	Forward P/E	13.59	EPS next Y	18.47	Insider Trans	-2.80%	Shs Float	102.07M	Perf Month	-9.05%
Income	1.04B	PEG	2.33	EPS next Q	2.34	Inst Own	95.49%	Short Float	0.65%	Perf Quarter	0.59%
Sales	9.58B	P/S	2.68	EPS this Y	12.70%	Inst Trans	-0.49%	Short Ratio	1.37	Perf Half Y	20.80%
Book/sh	92.84	P/B	2.70	EPS next Y	13.08%	ROA	3.35%	Short Interest	0.67M	Perf Year	5.54%
Cash/sh	18.47	P/C	13.59	EPS next 5Y	10.80%	ROE	10.64%	52W Range	195.29 - 278.86	Perf YTD	4.04%
Dividend Est.	3.50 (1.39%)	P/FCF	23.57	EPS past 5Y	13.58%	ROI	6.78%	52W High	-10.01%	Beta	0.75
Dividend TTM	3.40 (1.35%)	Quick Ratio	-	Sales past 5Y	2.35%	Gross Margin	75.87%	52W Low	28.50%	ATR (14)	5.08
Dividend Ex-Date	Mar 27, 2024	Current Ratio	-	EPS Y/Y TTM	-4.75%	Oper. Margin	19.82%	RSI (14)	29.39	Volatility	2.29% 1.65%
Employees	48000	Debt/Eq	0.70	Sales Y/Y TTM	-17.87%	Profit Margin	10.88%	Recom	2.13	Target Price	300.04
Option/Short	Yes / Yes	LT Debt/Eq	0.62	EPS Q/Q	-2.80%	Payout	33.76%	Rel Volume	1.58	Prev Close	256.92
Sales Surprise	-1.18%	EPS Surprise	1.31%	Sales Q/Q	4.37%	Earnings	Apr 25 BMO	Avg Volume	486.67K	Price	250.95
SMA20	-5.17%	SMA50	-7.22%	SMA200	5.27%	Trades		Volume	770,659	Change	-2.32%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-24	Upgrade	Citigroup	Neutral → Buy	$236 → $315
Feb-12-24	Upgrade	BMO Capital Markets	Underperform → Market Perform	$236 → $298
Jan-11-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$248 → $288
Jan-10-24	Initiated	TD Cowen	Outperform	$316
Aug-08-23	Downgrade	BMO Capital Markets	Market Perform → Underperform	$230 → $205
Jul-27-23	Downgrade	Raymond James	Strong Buy → Outperform	$260
Jun-20-23	Initiated	Morgan Stanley	Equal-Weight	$251
Feb-27-23	Upgrade	Goldman	Neutral → Buy	$290
Jan-20-23	Initiated	BMO Capital Markets	Market Perform	$260
Jan-18-23	Upgrade	Keefe Bruyette	Mkt Perform → Outperform	$303
Dec-15-22	Initiated	Citigroup	Neutral	$247
Oct-13-22	Upgrade	Piper Sandler	Neutral → Overweight	$250
Sep-26-22	Initiated	Credit Suisse	Outperform	$288
Jul-12-22	Initiated	Goldman	Neutral	$227
Apr-11-22	Resumed	BofA Securities	Underperform	$245
Feb-09-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$284 → $240
Dec-16-21	Initiated	Evercore ISI	In-line	$240
Nov-19-21	Initiated	Jefferies	Hold	$258
Oct-20-21	Downgrade	Wolfe Research	Outperform → Peer Perform	$283 → $244
Sep-10-21	Reiterated	MKM Partners	Buy	$250 → $285

Show Previous Ratings

Today 10:47AM	Wells Fargo Adjusts Willis Towers Watson's Price Target to $317 From $318 (MT Newswires)
09:43AM	Citigroup Adjusts Price Target on Willis Towers Watson to $312 From $315 (MT Newswires)
09:26AM	Jefferies Adjusts Price Target on Willis Towers Watson to $286 From $292 (MT Newswires)
08:23AM	Piper Sandler Adjusts Price Target on Willis Towers Watson to $303 From $297 (MT Newswires)
07:37AM	Evercore ISI Adjusts Willis Towers Watson Price Target to $295 From $290 (MT Newswires)
01:06AM	Loading…
01:06AM	Decoding Willis Towers Watson PLC (WTW): A Strategic SWOT Insight (GuruFocus.com)
Apr-25-24 01:01PM	Analyst Report: Willis Towers Watson Public Limited Company (Morningstar Research)
10:56AM	WTW Stock Earnings: Willis Towers Watson Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:00AM	Willis Towers (WTW) Q1 Earnings Beat, Revenues Rise Y/Y (Zacks)
09:30AM	Willis Towers Watson (WTW) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:56AM	Willis Towers Watson's Q1 Adjusted Earnings, Revenue Advance; 2024 Earnings, Revenue Outlook Issued (MT Newswires)
07:32AM	Willis Towers Watson PLC (WTW) Q1 2024 Earnings: Adjusted EPS Outperforms Analyst Expectations (GuruFocus.com)
06:00AM	WTW Reports First Quarter 2024 Earnings (GlobeNewswire)
Apr-22-24 09:16AM	Unveiling Willis Towers Watson (WTW) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
08:00AM	WTW appoints Lombardo Chair of the Real Estate, Hospitality, and Leisure (REHL) Division, CRB NA (GlobeNewswire)
10:40AM	Loading…
Apr-19-24 10:40AM	Will Willis Towers' (WTW) Beat Streak Continue in Q1 Earnings? (Zacks)
Apr-18-24 10:01AM	Willis Towers Watson (WTW) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-17-24 09:50AM	Verita launches new Pandemic Protection Package Policy (GlobeNewswire)
Apr-16-24 10:49AM	Companies enhancing M&A retention strategies, WTW survey finds (GlobeNewswire)
06:36AM	WTW announces appointment of Nick Dussuyer as Head of France and Head of Corporate Risk & Broking France (GlobeNewswire)
05:45AM	Energy market conditions creating story of two halves with widening desirability gulf, according to latest WTW Energy Market Review (GlobeNewswire)
Apr-08-24 04:40PM	Verita announces claims leadership team (GlobeNewswire)
03:00AM	WTW announces appointment of Sean Plankey as Global Leader Cybersecurity Software (GlobeNewswire)
Apr-05-24 09:00AM	WTW to Announce First Quarter Earnings on April 25, 2024 (GlobeNewswire)
Apr-03-24 10:02AM	Global M&A endures headwinds with pickup in first-quarter deal closures (GlobeNewswire)
Mar-28-24 03:22PM	13 High Growth Value Stocks to Invest in According to Seth Klarman (Insider Monkey)
Mar-26-24 07:05AM	Willis Towers Watson PLC's Dividend Analysis (GuruFocus.com)
Mar-20-24 07:18AM	Health and safety emerges as top risk facing global directors according to WTW's and Clyde & Co's latest survey (GlobeNewswire)
Mar-18-24 04:30AM	WTW announces USAID funding for transformative climate finance solution to scale up adaptation investment in vulnerable countries (GlobeNewswire)
Mar-14-24 05:30AM	Hard market softening for construction sector, but inflation pressures still loom over insurance industry (GlobeNewswire)
11:31AM	Loading…
Mar-07-24 11:31AM	Why Is Willis Towers Watson (WTW) Up 1.1% Since Last Earnings Report? (Zacks)
05:15AM	Optimism despite disruptive forces in retail sector: WTW's Global Retail Survey (GlobeNewswire)
Mar-04-24 11:00AM	WTW deepens talent with addition of three strategic hires, CRB NA (GlobeNewswire)
Feb-29-24 04:00PM	Verita Announces Two Strategic Hires (GlobeNewswire)
Feb-28-24 09:22AM	WTW Prices Offering of $750,000,000 of Senior Notes (GlobeNewswire)
Feb-27-24 10:59AM	WTW Announces Regular Quarterly Dividend (GlobeNewswire)
Feb-26-24 10:17AM	Global pension assets rebound past USD 55 Trillion (GlobeNewswire)
Feb-23-24 12:09AM	Decoding Willis Towers Watson PLC (WTW): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 12:00PM	Willis Towers Watson (WTW) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:44AM	WTW advises on CA$923 million annuity transaction for Ford of Canada involving RBC Insurance, Sun Life and Desjardins Group (PR Newswire)
Feb-14-24 08:21PM	Analyst Report: Willis Towers Watson Public Limited Company (Morningstar Research)
Feb-12-24 08:49AM	WTW enters co-brokerage agreement with the Solomon Agency Corporation (GlobeNewswire)
Feb-10-24 03:00AM	First Eagle Investment Bolsters Stake in Willis Towers Watson PLC (GuruFocus.com)
Feb-07-24 09:00PM	WTW appoints Roy Nakazawa as Head of Japan and Head of Corporate Risk & Broking Japan (GlobeNewswire)
02:22PM	Willis Towers Stock Pops On Strongest Earnings Growth In A Year (Investor's Business Daily)
10:38AM	Willis Towers Watson Public Limited Company (NASDAQ:WTW) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-06-24 12:30PM	Analyst Report: Willis Towers Watson Public Limited Company (Morningstar Research) +7.18%
09:30AM	Compared to Estimates, Willis Towers Watson (WTW) Q4 Earnings: A Look at Key Metrics (Zacks)
09:25AM	Willis Towers (WTW) Q4 Earnings Top Estimates, Revenues Up Y/Y (Zacks)
07:13AM	Willis Towers Watson beats profit estimates on risk, brokerage strength (Reuters)
07:10AM	Willis Towers Watson (WTW) Q4 Earnings and Revenues Beat Estimates (Zacks)
06:32AM	Willis Towers Watson PLC (WTW) Posts Strong Earnings Growth in Q4 and Full Year 2023 (GuruFocus.com)
06:00AM	WTW Reports Fourth Quarter and Full Year 2023 Earnings (GlobeNewswire)
Feb-01-24 09:22AM	Here's What to Expect From Willis Towers' (WTW) Q4 Earnings (Zacks)
09:15AM	Ahead of Willis Towers Watson (WTW) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Jan-30-24 10:00AM	Willis Towers Watson (WTW) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-29-24 08:32AM	WTW launches tailored cyber insurance solution for small and medium-sized enterprises (SME) (GlobeNewswire)
Jan-25-24 08:18AM	Companies are making big changes to their leave programs in an effort to hold onto workers (Fortune)
Jan-24-24 09:05AM	North American companies continue to link executive pay programs to ESG measures, WTW study finds (GlobeNewswire)
Jan-22-24 09:05AM	Majority of employers will change their leave programs in the next two years, WTW survey finds (GlobeNewswire)
08:00AM	WTW appoints Jody Yee East Coast Leader for the Technology, Media & Telecommunications (TMT) Industry Division (GlobeNewswire)
Jan-17-24 08:00AM	WTW launches new large and complex client growth team (GlobeNewswire)
Jan-10-24 09:00AM	Global M&A poised for growth as storm clouds recede (GlobeNewswire)
Jan-09-24 04:05PM	WTW to Announce Fourth Quarter and Full Year Earnings on February 6, 2024 (GlobeNewswire)
Jan-04-24 07:47AM	Here's Why Hold Strategy is Apt for Willis Towers (WTW) Now (Zacks)
07:07AM	Pension plans at the largest companies in the U.S. reached 100% funding status in 2023, according to a WTW analysis (Fortune)
Jan-03-24 08:23AM	UPDATE 1-U.S. insurer AIG leads policy for Japan Airlines plane -sources (Reuters)
06:42AM	U.S. insurer AIG leads policy for Japan Airlines plane -sources (Reuters)
Jan-02-24 10:23AM	Funded status of largest U.S. corporate pension plans ends 2023 at 100% (GlobeNewswire)
Dec-27-23 05:10AM	Willis Towers Watson PLC's Dividend Analysis (GuruFocus.com)
Dec-14-23 03:30AM	WTW set to acquire AIMUW in major boost to risk advisory and broking presence in Italy (GlobeNewswire)
Dec-12-23 09:29AM	WTW launches CyProtect Bermuda, reinventing distinction in Cyber Insurance (GlobeNewswire)
Dec-11-23 08:00AM	U.S. commercial insurance rates continue to demonstrate aggregate increase above 6% (GlobeNewswire)
Dec-07-23 05:21PM	15 Best UK Insurance Companies Heading into 2024 (Insider Monkey)
10:21AM	US pay raises to remain high in 2024, WTW survey finds (GlobeNewswire)
Dec-06-23 07:57AM	Oshi Health Announces Agreement with WTW to Give Employers Access to Comprehensive Digestive Health Support for Their Employees (PR Newswire)
Dec-05-23 04:05PM	WTW Announces Regular Quarterly Dividend (GlobeNewswire)
Dec-04-23 08:00AM	WTW appoints Chris Condello to Head Newly Created Asia Risk Division within CRB, North America (GlobeNewswire)
Nov-30-23 07:44AM	Should You Retain Willis Towers (WTW) Stock in Your Portfolio? (Zacks)
Nov-29-23 09:06AM	Global healthcare benefit cost increases projected to largely continue into 2024, WTW survey finds (GlobeNewswire)
06:00AM	Debt-distressed countries more likely to turn to non-traditional bailout options, according to WTW's political risk index (GlobeNewswire)
Nov-27-23 12:46PM	Sovereign wealth funds take record share of global asset ownership (GlobeNewswire)
Nov-14-23 12:50PM	12 Best Value Stocks To Buy Heading Into 2024 (Picked By Seth Klarman) (Insider Monkey)
Nov-13-23 04:03PM	Charles Brandes' Firm Amplifies Stake in Willis Towers Watson PLC by 201.27% (GuruFocus.com)
04:03PM	Charles Brandes Amplifies Stake in Willis Towers Watson PLC by 201.27% (GuruFocus.com)
Nov-08-23 05:41AM	Power Sector Faces Challenging, Unchartered Waters as Trilemma of Tension endures, says WTW (GlobeNewswire)
Nov-02-23 11:34AM	Some Surprise Names Led The S&P 500 In October (Investor's Business Daily)
Nov-01-23 07:00AM	ESG catapults reputational risk into the top five, Willis Towers Watson reports (GlobeNewswire)
Oct-28-23 02:32PM	Willis Towers Watson Public Limited Company (NASDAQ:WTW) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 12:14PM	Arthur J. Gallagher (AJG) Q3 Earnings Top Estimates, Rise Y/Y (Zacks)
Oct-26-23 08:24PM	Analyst Report: Willis Towers Watson Public Limited Company (Morningstar Research) +10.27%
10:52AM	Willis Towers (WTW) Q3 Earnings Surpass, Revenues Rise Y/Y (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Willis Towers Watson (WTW) Q3 Earnings (Zacks)
07:50AM	Willis Towers Watson PLC (WTW) Reports Q3 2023 Earnings (GuruFocus.com)
07:42AM	WTW tops Street consensus as demand for its services solidifies (Reuters)
07:15AM	Willis Towers Watson (WTW) Q3 Earnings and Revenues Top Estimates (Zacks)
06:00AM	WTW Reports Third Quarter 2023 Earnings (GlobeNewswire)
Oct-23-23 12:00PM	Top 500 investment managers see assets drop by $18 trillion (GlobeNewswire)
07:56AM	Willis Towers (WTW) to Report Q3 Earnings: What to Expect? (Zacks)
Oct-20-23 09:45AM	U.S. employers target healthcare costs and mental healthcare as they look toward 2024 (GlobeNewswire)

Willis Towers Watson Plc engages in the provision of advisory, broking, and solutions services. It operates through the following segments: Health, Wealth, and Career (HCW), Risk and Broking (R&B), and Corporate and Other. The HCW segment provides an array of advice, broking, solutions, and technology for employee benefit plans, institutional investors, compensation and career programs, and the employee experience overall. The R&B segment focuses on a broad range of risk advice, insurance brokerage, and consulting services to clients globally, ranging from small businesses to multinational corporations. The company was founded in 1828 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Qureshi Imran Ahmed	Head of North America	Apr 15 '24	Option Exercise	0.00	1	0	4,907	Apr 17 07:12 PM
Hess Carl Aaron	Chief Executive Officer	Apr 15 '24	Option Exercise	0.00	8	0	79,672	Apr 17 07:11 PM
Pullum Anne	Head of Europe	Apr 15 '24	Option Exercise	0.00	1	0	15,596	Apr 17 07:09 PM
Gebauer Julie Jarecke	Head of Health, Wealth &Career	Apr 15 '24	Option Exercise	0.00	1	0	73,901	Apr 17 07:07 PM
Furman Matthew	General Counsel	Apr 15 '24	Option Exercise	0.00	1	0	34,804	Apr 17 07:05 PM
Garrard Adam	Head of Risk & Broking	Apr 15 '24	Option Exercise	0.00	1	0	16,132	Apr 17 07:06 PM
Krasner Andrew Jay	Chief Financial Officer	Apr 15 '24	Option Exercise	0.00	1	0	7,963	Apr 17 07:00 PM
Krasner Andrew Jay	Chief Financial Officer	Mar 01 '24	Sale	272.13	1,100	299,346	4,170	Mar 05 04:01 PM
Gebauer Julie Jarecke	Head of Health, Wealth &Career	Feb 20 '24	Sale	276.03	5,000	1,380,144	68,574	Feb 22 04:00 PM
Garrard Adam	Head of Risk & Broking	Feb 08 '24	Sale	270.41	5,400	1,460,214	11,259	Feb 12 04:00 PM
Thomson-Hall Pamela	Head of International	Nov 09 '23	Sale	238.87	330	78,827	3,324	Nov 13 04:02 PM
Gebauer Julie Jarecke	Head of Health, Wealth &Career	Jul 03 '23	Sale	231.69	2,000	463,384	75,240	Jul 05 04:01 PM
Pullum Anne	Head of Europe	Jun 07 '23	Sale	224.45	5,000	1,122,230	12,791	Jun 09 04:00 PM
Gebauer Julie Jarecke	Head of Health, Wealth &Career	Jun 01 '23	Sale	218.35	2,500	545,868	77,240	Jun 01 04:01 PM
Gebauer Julie Jarecke	Head of Health, Wealth &Career	May 01 '23	Sale	231.44	2,500	578,590	79,740	May 02 04:01 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PIRS

Pieris Pharmaceuticals Inc

WTW

Willis Towers Watson Public Limited Co

Upgrade your FINVIZ experience